- PhD Level
- Posts
- ⚡️Mito Boost KOs Lung Cancer💥
⚡️Mito Boost KOs Lung Cancer💥
Daily news that is actually intellectually stimulating.
Anthony Ao
August 07, 2025
In partnership with
Training Generative AI? It starts with the right data.
Your AI is only as good as the data you feed it. If you're building or fine-tuning generative models, Shutterstock offers enterprise-grade training data across images, video, 3D, audio, and templates—all rights-cleared and enriched with 20+ years of human-reviewed metadata.
With 600M+ assets and scalable licensing, our datasets help leading AI teams accelerate development, simplify procurement, and boost model performance—safely and efficiently.
Book a 30-minute discovery call to explore how our multimodal catalog supports smarter model training. Qualified decision-makers will receive a $100 Amazon gift card.
For complete terms and conditions, see the offer page.
🧬 Mitochondrial “Power‑Ups” Turn Cisplatin into a Two‑Pronged Attack on Lung Cancer
Researchers in China isolated healthy, energy‑rich mitochondria from human heart cells and injected them directly into non‑small‑cell lung‑cancer (NSCLC) models. When this mitochondrial “boost” was paired with the standard chemotherapy drug cisplatin, the followings were observed.
Tumour cells became twice as sensitive to cisplatin (IC₅₀ fell from 12.93 µM to 6.7 µM) and shrank far more in mice.
The Warburg effect was reversed: glycolysis genes dropped while oxidative‑phosphorylation genes rose, stripping tumours of their favoured fuel source.
Immune power bounced back. T cells and natural‑killer cells regained mitochondrial activity, flooded the tumour micro‑environment, and showed stronger anti‑tumour signals.
No extra toxicity appeared in body weight or organ checks, hinting at a safer combination strategy.
Why it matters:
Chemotherapy often weakens the very immune cells it needs for durable cancer control, and tumours can even steal mitochondria from those cells. By “re‑arming” immune cells and simultaneously disarming the tumour’s metabolism, mitochondrial transplantation could extend the life‑saving reach of cisplatin and other cytotoxic drugs—especially for patients whose lung cancers resist today’s chemo‑immunotherapy regimens.
Did you find this news intellectually stimulating? |
Tired of compliance drama?
That enterprise deal? They just asked for SOC 2. Traditional path: 6 months, $100K.
With Delve: 15 hours. Our AI handles the busywork, and our experts help you close faster.
Lovable did it in 20 hours.
11x unlocked $2.3M.
Book a demo—code BEEHIV1K gets you $1,000 off.
Some affiliate links we endorse:
Stay curious,
Anthony Ao
The PhDLevel Team
☕️🐻 Powered by caffeine & curiosity